Methods for treating fungal infections
AssigneeBrigham Young University
InventorsCarl Genberg, Chad S. Beus, Paul B. Savage
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
Claims20
A method of therapeutically treating a patient having an echinocandin- or fluconazole-resistant fungal infection associated with Candida auris, the method comprising:
- identifying a patient having an echinocandin- or fluconazole-resistant Candida auris infection;
- administering a treatment composition to the patient, the treatment composition including one or more CSA compounds of Formula IV:
- where,
- R3, R7, and R12 are unsubstituted aminoalkyloxy;
- and
- R18 is unsubstituted alkylaminoalkyl;
- and
- the treatment composition killing or deactivating Candida auris to therapeutically treat the patient.
A method of therapeutically treating an echinocandin- or fluconazole-resistant fungal infection associated with Candida auris, the method comprising:
- identifying a patient having an echinocandin- or fluconazole-resistant fungal infection;
- administering a treatment composition to an open wound or surgical site of the patient, the treatment composition being configured as a wash or spray and including one or more CSA compounds of Formula IV:
- where,
- R3, R7, and R12 are unsubstituted aminoalkyloxy;
- and
- R18 is unsubstituted alkylaminoalkyl;
- and
- the treatment composition killing or deactivating Candida auris to therapeutically treat the echinocandin- or fluconazole-resistant fungal infection at the open wound or surgical site.
A method of therapeutically treating a echinocandin- or fluconazole-resistant fungal infection associated with Candida auris, the method comprising:
- applying a treatment composition to a medical device prior to use of the medical device on a patient, the treatment composition including one or more CSA compounds of Formula IV:
- where,
- R3, R7, and R12 are unsubstituted aminoalkyloxy;
- and
- R18 is unsubstituted alkylaminoalkyl;
- and
- the treatment composition killing or deactivating Candida auris to therapeutically treat the echinocandin- or fluconazole-resistant fungal infection.
Dependencies are inferred from the claim text.